- Market Capitalization, $K 1,082,751
- Shares Outstanding, K 92,622
- Annual Sales, $ 176,320 K
- Annual Income, $ -189,290 K
- 60-Month Beta 0.93
- Price/Sales 6.16
- Price/Cash Flow N/A
- Price/Book 4.08
|Period||Period Low||Period High||Performance|
| || |
-0.86 (-7.10%)since 08/20/21
| || |
-15.71 (-58.27%)since 06/18/21
| || |
-33.26 (-74.72%)since 09/18/20
FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.
FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company's Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl...
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
Morning Markets Sep S&P 500 futures this morning are down -0.34% and are only modestly above Thursday’s 4-week low. Stocks are lower on concern about faltering economic growth from the spread of the...
Aug. 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced...
FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September...
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment...
FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
? Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis.
|Fibrogen Inc CS|
|Biotechnology Index NYSE ETF|
|FTSE All-World Ex-US Smcp Idx ETF Vanguard|
|Alps Medical Breakthroughs ETF|
|FTSE EM ETF Vanguard|
|Ishares Genomics Immunology and Healthcare ETF|
|3rd Resistance Point||12.30|
|2nd Resistance Point||12.08|
|1st Resistance Point||11.88|
|1st Support Level||11.46|
|2nd Support Level||11.24|
|3rd Support Level||11.04|